Tricyclic quinoline and quinoxaline derivatives

US10118926B2 · kind B2 · utility

Assignees

• Abb Vie Deutschland Gmbh & Co. KG · DE
• Abb Vie Inc. · US

Inventors

• Hannes Fiepko KOOLMAN · North Chicago, US
• Wilfried Braje · Ludwigshafen, DE
• Helmut Mack · Ludwigshafen, DE
• Andreas Haupt · Ludwigshafen, DE
• Ana-Lucia Relo · Ludwigshafen, DE
• Karla Drescher · Ludwigshafen, DE
• Margaretha Henrica Maria Bakker · Ludwigshafen, DE
• Viktor Lakics · Budapest, HU
• Carolin Hoft · Ludwigshafen, DE
• Ruxu Xu · Tianjin, CN
• Xiaona Zhao · Tianjin, CN

Key dates

• Filing date: Sep 13, 2013
• Grant date: Nov 6, 2018
• Expiry date: Sep 13, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.